Acne Game-Changers Imperative to Countering Poor Compliance
- Acne treatment market saturated with mainstay drugs over 30 years old
- Novel combination products needed to ‘simplify the treatment regimen of acne and improve patient compliance,’ says analyst
Acne Game-Changers Imperative to Countering Poor Patient Compliance, says GlobalData Analyst
LONDON, UK (GlobalData), 25 September 2013 - Despite its considerable patient population, the acne treatment market has remained stagnant for the last decade, and a significant unmet need exists for single drugs or combination products that improve patient compliance while providing optimal efficacy, says an analyst with research and consulting firm GlobalData.
According to Dr Samantha Fernando, GlobalData’s Therapy Area Analyst covering Immunology, acne patient compliance is notoriously poor due to a significant burden of usage caused by the majority of acne topical drugs, typically requiring twice-daily application.
Fernando says: “The lack of dedicated research activity towards novel and more convenient acne treatments has been attributed to pharmaceutical companies viewing topicals — the mainstay of acne therapy — as too cheap, resulting in a subsequent poor return on their investment.
“What we are seeing instead is a trend with the reformulation of existing products and the formulation of fixed-dose combinations, as the multifaceted and chronic disease mechanism of acne means that two or more medications must be used both concurrently and long-term.”
Currently, the acne market is saturated with mainstay drugs that are over 30 years old. However, Galderma recently targeted the sizeable and untapped pediatric acne population by obtaining a label expansion for children under 12 years old for its combination product, Epiduo (benzoyl peroxide and adapalene) in 2013.
While the cost of developing further combination acne products is proving a colossal barrier to patient accessibility, Fernando believes it is crucial to weigh up this high cost against that of patients using multiple acne products, which are associated with decreased compliance.
“It is clear that a much-needed game-changer is still highly sought in this arena; but, in the meantime, the development of combination products that both simplify the treatment regimen of acne and improve patient compliance is imperative,” Fernando concludes.
-NOTES TO EDITORS-
- Comment provided by Dr Samantha Fernando, GlobalData’s Therapy Area Analyst covering Immunology.
For guidelines on how to cite GlobalData, please see: http://www.globaldata.com/QuotingGlobalData.aspx
GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.
For more information, please contact our Press Office on +44 (0)1204 543 537 or at email@example.com.
Gain access to free expert analysis on the latest developments in your industry by connecting with us on:
Posted: September 2013